2023 Diabetes Preserved Ejection Fraction 
DAIC
JUNE 21, 2024
announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our healthcare system. “Our
DAIC
FEBRUARY 29, 2024
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24 12:15 p.m.
DAIC
MARCH 26, 2025
live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 2023; Oct;29(10):1412-1451. J Card Fail.
Circulation
OCTOBER 13, 2023
Circulation, Volume 148, Issue 24 , Page 1945-1957, December 12, 2023. BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction.
Cardiometabolic Health Congress
JULY 25, 2023
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] I think we live in a very exciting time right now for those who work in diabetes and cardiovascular disease.
Expert insights. Personalized for you.
105 
Let's personalize your content